疫苗合約製造市場 - 疫苗類型（減毒、去活化）、營運規模（商業、臨床）、服務（灌裝、散裝）、產品類型（組合、單一）、應用、最終用戶、全球預測（2024 年 -第2032章

Vaccine Contract Manufacturing Market - Vaccine Type (Attenuated, Inactivated), Scale of Operation (Commercial, Clinical), Service (Fill-finish, Bulk), Product Type (Combination, Single), Application, End-user, Global Forecast (2024 - 2032)

出版日期: 2024年06月03日 | 出版商:

Global Market Insights Inc. | 英文 220 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在外包趨勢不斷上升的推動下，全球疫苗合約製造市場 2024 年至 2032 年間的複合年成長率將達到 11%。製藥公司擴大外包疫苗生產，以降低成本並專注於核心活動。隨著製藥公司越來越注重核心競爭力並尋求成本效率，他們轉向專業的合約製造商來處理疫苗生產。外包使公司能夠利用先進的技術和專業知識，而無需投資昂貴的基礎設施。這一趨勢是由新疫苗對可擴展性、靈活性和加快上市時間的需求所推動的。

例如，2024 年 5 月，全球領先的製藥公司賽諾菲宣布一項超過 10 億歐元（10.8 億美元）的重大投資，以擴大法國三個基地的生物產能。這項投資是更廣泛的 35 億歐元計畫的一部分，旨在減少法國和歐盟對外部製造來源的依賴。該計劃旨在增強供應鏈的安全性和彈性，並與歐盟的健康主權理念保持一致。這一概念在 COVID-19 大流行後受到重視，重點是加強製藥系統、疫苗和醫療產品的製造能力，以及改善威脅偵測和回應機制。

此外，合約製造商提供監管合規性和品質保證，進一步增強了它們在不斷擴大的疫苗市場中的吸引力。

整個疫苗合約製造業根據疫苗類型、營運規模、服務、產品類型、應用、最終用戶和地區進行分類。

由於對針對各種傳染病的可靠且安全的疫苗的需求，去活化疫苗合約製造市場將在 2024 年至 2032 年期間實現可觀的成長。去活化疫苗利用去活化的病原體來刺激免疫反應，對於預防減毒活疫苗不適合的疾病至關重要。生產技術的進步，加上全球健康問題和疫情的日益嚴重，推動了對專業製造的需求。此外，對高品質、一致的疫苗生產的監管要求進一步增加了對去活化疫苗合約服務的需求。

到 2032 年，臨床細分市場將佔據相當大的市場佔有率。隨著臨床試驗的進展，製藥公司需要專門的生產設施來大量生產疫苗進行測試和評估。合約製造商提供必要的專業知識、技術和靈活性來處理不同規模的生產，同時確保遵守監管標準。此外，外包這些營運有助於簡化開發時間表並降低成本，從而提高整體專案效率。

由於嚴格的監管標準需要專業化的生產能力，歐洲疫苗合約製造市場將在 2024 年至 2032 年大幅成長。對生物製藥基礎設施的投資增加和製造技術的進步也發揮了作用。歐洲專注於減少對非歐盟生產的依賴並增強供應鏈的彈性，特別是在疫情後，這推動了需求。此外，不斷成長的公共和私營部門合作以及對可擴展生產解決方案的需求，進一步推動了該地區的合約製造市場。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 12 章：公司簡介

Ajinomoto Co., Inc.
Bavarian Nordic A/S
Catalent, Inc
Charles River Laboratories International Inc.
Curia Global, Inc.
Cytovance Biologics (Hepalink)
Emergent BioSolutions Inc.
Fujifilm Holdings Corporation
Goodwin Biotechnology Inc.
Gedeon Richter (Richter-Helm BioLogics)
ICON PLC
IDT Biologika GmbH
Lonza Group AG
Recipharm AB
Syngene International Limited

簡介目錄

Product Code: 9726

Global Vaccine Contract Manufacturing Market will depict 11% CAGR between 2024 and 2032, driven by the rising outsourcing trends. Pharmaceutical companies increasingly outsource vaccine production to reduce costs and focus on core activities. As pharmaceutical companies increasingly focus on core competencies and seek cost efficiencies, they turn to specialized contract manufacturers to handle vaccine production. Outsourcing allows companies to leverage advanced technologies and expertise without investing in costly infrastructure. This trend is driven by the need for scalability, flexibility, and accelerated time-to-market for new vaccines.

For instance, in May 2024, Sanofi, a leading global pharmaceutical company, announced a major investment exceeding €1 billion ($1.08 billion) to expand bioproduction capacity at three sites in France. This investment is part of a broader €3.5 billion program aimed at reducing France's and the EU's reliance on external manufacturing sources. The initiative seeks to enhance supply chain security and resilience, aligning with the EU's health sovereignty concept. This concept, which gained prominence after the COVID-19 pandemic, focuses on strengthening pharmaceutical systems, manufacturing capacities for vaccines and medical products, and improving threat detection and response mechanisms.

In addition, contract manufacturers offer regulatory compliance and quality assurance, further boosting their appeal in the expanding vaccine market.

The overall vaccine contract manufacturing industry is categorized based on vaccine type, scale of operation, service, product type, application, end-user, and region.

The inactivated vaccine contract manufacturing market will drive commendable gains over 2024-2032, propelled by the need for reliable and safe vaccines against various infectious diseases. Inactivated vaccines, which use killed pathogens to stimulate immune responses, are crucial for preventing diseases where live attenuated vaccines are not suitable. Advances in production technology, coupled with rising global health concerns and outbreaks, drive the need for specialized manufacturing. Additionally, regulatory requirements for high-quality, consistent vaccine production further boost the demand for inactivated vaccine contract services.

The clinical segment will capture a substantial market share by 2032. The demand for vaccine contract manufacturing at a clinical scale is stimulated by the need for efficient and scalable production during vaccine development. As clinical trials progress, pharmaceutical companies require specialized manufacturing facilities to produce vaccines in large quantities for testing and evaluation. Contract manufacturers offer the necessary expertise, technology, and flexibility to handle varying scales of production while ensuring compliance with regulatory standards. Additionally, outsourcing these operations helps streamline development timelines and reduces costs, enhancing overall project efficiency.

Europe vaccine contract manufacturing market will grow substantially over 2024-2032 due to stringent regulatory standards that necessitate specialized production capabilities. Increased investment in biopharmaceutical infrastructure and advancements in manufacturing technologies also play a role. Europe's focus on reducing dependence on non-EU production and enhancing supply chain resilience, particularly post-pandemic, drives demand. Additionally, growing public and private sector collaborations, alongside the need for scalable production solutions, further boost the region's contract manufacturing market.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising demand for vaccines
  - 3.2.1.2 Increasing adoption of outsourcing services
  - 3.2.1.3 Technological advancements in vaccine technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory requirements
  - 3.2.2.2 Increasing cost of vaccines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Attenuated
5.3 Inactivated
5.4 Subunit-based
5.5 Toxoid-based
5.6 DNA-based

Chapter 6 Market Estimates and Forecast, By Scale of Operation, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Commercial
6.3 Clinical
6.4 Preclinical

Chapter 7 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Fill-finish
7.3 Bulk vaccines

Chapter 8 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Combination vaccine
8.3 Single vaccine

Chapter 9 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Human
9.3 Veterinary

Chapter 10 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 Pharmaceutical & biotechnology companies
10.3 Academic and research institutes

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

11.1 Key trends
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Netherlands
- 11.3.7 Rest of Europe
11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.4.6 Rest of Asia Pacific
11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest of Latin America
11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 UAE
- 11.6.4 Rest of Middle East and Africa